DNLI - CIK 0001714899
The table below shows Denali Therapeutics Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $387.63M | $90.96M | $141.21M | $56.95M | $90.64M | $74.68M |
| Short-term investments | $600.06M | $757.24M | $757.75M | $760.98M | $745.92M | $821.37M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.02B |
| $882.60M |
| $934.71M |
| $878.64M |
| $868.84M |
| $928.38M |
| Property, plant & equipment | $51.73M | $53.73M | $58.72M | $57.77M | $50.82M | $48.08M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.27B | $1.06B | $1.17B | $1.27B | $1.45B | $1.50B |
| Accounts payable | $40.38M | $6.75M | $10.84M | $8.46M | $9.59M | $13.94M |
| Total current liabilities | $110.16M | $90.15M | $91.06M | $91.88M | $87.09M | $74.53M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $339.93M | $129.42M | $139.19M | $148.66M | $135.52M | $115.51M |
| Retained earnings | -$2.18B | -$1.92B | -$1.80B | -$1.67B | -$1.42B | -$1.32B |
| Total equity | $926.10M | $926.20M | $1.03B | $1.12B | $1.32B | $1.39B |